Cloroquina e Hidroxicloroquina en el tratamiento de la COVID-19
References
1. OMS [Internet]. Suecia: OMS; 2020 [actua¬lizado 27 de abril 2020; citado 10 de junio de 2020]. Disponible en: https://www.who.int/es/news-room/detail/27-04-2020-who-timeline---covid-19
2. OMS [Internet]. Suecia: OMS; 2020 [actua¬lizado 11 de marzo 2020; citado 10 de ju¬nio de 2020]. Disponible en: https://www.who.int/dg/speeches/detail/who-direc¬tor-general-s-opening-remarks-at-the-me¬dia-briefing-on-covid-19---11-march-2020.
3. Gautret P, Lagier LC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychlo¬roquine and azithromycin as a treatment of COVID-19: results of anopen-label non-randomized clinical trial, International Journal of Antimicrobial Agents [Internet]. 2020 [citado 23 de junio 2020]; 59(1): 1-24. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105949.
4. La cloroquina y la hidroxicloroquina au¬mentan el riesgo de muerte en pacientes con coronavirus. INFOMED [Internet]. La Habana: ECIMED; 1992 [actualizado 23 de mayo 2020; citado 22 de junio 2020. Disponible en: http://www.sld.cu/node?i-wp_post=2020%2F05%2F25%2FLa%20cloroquina%20y%20la%20hidroxicloro-quina%20aumentan%20el%20riesgo%20de%20muerte%20en%20pacientes%20con%20coronavirus%2F184103&iwp_
5. Gérard A, Romani S, Fresse A, Viard D, Pa¬rassol N, Granvuillemin G, et al. ‘‘Off-label’’ use of hydroxychloroquine, azithromy¬cin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies [Internet]. 2020 [citado 23 de junio 2020]; 45(3): 1-9. Disponible en: https://doi.org/10.1016/j.therap.2020.05.002
6. Silva MG, Almeida FF, Sousa V, Araú¬jo MA, Cardoso G, Brito M, et al. Chlo-roquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe res¬piratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a ran-domized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study).MedRxiv [Internet]. 2020 [citado 23 de junio 2020]; 24(1): 1-31 Disponible en https://www.medrxiv.org/conten-t/10.1101/2020.04.07.20056424v1.full.pdf.
7. Protocolo de Actuación Nacional para la COVID-19 versión 1.4. MINSAP [In¬ternet] mayo del 2020 [citado 23 de ju¬nio de 2020]. Disponible en: https://fi¬les.sld.cu/editorhome/files/2020/05/MINSAP_Protocolo-de-Actuaci%¬C3%B3n-Nacional-para-la-COVID-19_versi%C3%B3n-1.4_mayo-2020.pdf
2. OMS [Internet]. Suecia: OMS; 2020 [actua¬lizado 11 de marzo 2020; citado 10 de ju¬nio de 2020]. Disponible en: https://www.who.int/dg/speeches/detail/who-direc¬tor-general-s-opening-remarks-at-the-me¬dia-briefing-on-covid-19---11-march-2020.
3. Gautret P, Lagier LC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychlo¬roquine and azithromycin as a treatment of COVID-19: results of anopen-label non-randomized clinical trial, International Journal of Antimicrobial Agents [Internet]. 2020 [citado 23 de junio 2020]; 59(1): 1-24. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105949.
4. La cloroquina y la hidroxicloroquina au¬mentan el riesgo de muerte en pacientes con coronavirus. INFOMED [Internet]. La Habana: ECIMED; 1992 [actualizado 23 de mayo 2020; citado 22 de junio 2020. Disponible en: http://www.sld.cu/node?i-wp_post=2020%2F05%2F25%2FLa%20cloroquina%20y%20la%20hidroxicloro-quina%20aumentan%20el%20riesgo%20de%20muerte%20en%20pacientes%20con%20coronavirus%2F184103&iwp_
5. Gérard A, Romani S, Fresse A, Viard D, Pa¬rassol N, Granvuillemin G, et al. ‘‘Off-label’’ use of hydroxychloroquine, azithromy¬cin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies [Internet]. 2020 [citado 23 de junio 2020]; 45(3): 1-9. Disponible en: https://doi.org/10.1016/j.therap.2020.05.002
6. Silva MG, Almeida FF, Sousa V, Araú¬jo MA, Cardoso G, Brito M, et al. Chlo-roquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe res¬piratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a ran-domized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study).MedRxiv [Internet]. 2020 [citado 23 de junio 2020]; 24(1): 1-31 Disponible en https://www.medrxiv.org/conten-t/10.1101/2020.04.07.20056424v1.full.pdf.
7. Protocolo de Actuación Nacional para la COVID-19 versión 1.4. MINSAP [In¬ternet] mayo del 2020 [citado 23 de ju¬nio de 2020]. Disponible en: https://fi¬les.sld.cu/editorhome/files/2020/05/MINSAP_Protocolo-de-Actuaci%¬C3%B3n-Nacional-para-la-COVID-19_versi%C3%B3n-1.4_mayo-2020.pdf
Downloads
Published
2020-06-24
How to Cite
1.
Hernández-García OL, Rodríguez-Venegas E de la C. Cloroquina e Hidroxicloroquina en el tratamiento de la COVID-19. Rev 16 de abril [Internet]. 2020 Jun. 24 [cited 2024 Dec. 22];59(276):e962. Available from: https://rev16deabril.sld.cu/index.php/16_04/article/view/962
Issue
Section
Editorial
License
Those authors who have publications with this journal, accept the following terms:
The authors will retain their copyright and guarantee the journal the right of first publication of your work, which will be under a Creative license Commons Attribution-NonCommercial-ShareAlike 4.0 International . (CC BY-NC-SA 4.0).
The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (eg:deposit it in an institutional telemat
